The TAME trial reported that metformin 1500mg daily significantly reduced the combined risk of cardiovascular disease, cancer, cognitive decline, and death in non-diabetic adults aged 65-79, with biological aging markers also showing improvement. This is the first large-scale RCT demonstrating pharmacological extension of healthspan.
Phase 2 clinical data shows D+Q senolytic combination reduces senescent cell burden by 30-50% in adipose tissue, with measurable improvements in physical function (6-minute walk distance, grip strength) in patients with diabetic kidney disease. First human evidence that senescent cell clearance translates to functional benefit.
Verve Therapeutics reported durable 55% LDL-C reduction at 12 months in VERVE-101 Phase 1b trial using in vivo base editing of PCSK9 gene. Single-dose, permanent gene modification approach could replace lifelong statin therapy. Safety monitoring ongoing with no serious adverse events to date.
New multi-omics clock combining epigenetic, proteomic, and metabolomic data achieves MAE of 1.8 years for biological age prediction. Outperforms single-modality clocks and identifies actionable intervention targets. Commercial applications in health monitoring and clinical trials as endpoint.
Japanese research team demonstrates 10% engraftment rate of iPSC-derived cardiomyocyte patches in macaque hearts with improved ejection fraction. Electrical coupling confirmed. Key milestone toward clinical translation for heart failure. Human trials expected 2027.
Major pharma acquisitions in senolytics and NAD+ space signal market validation. Altos Labs, Calico, and Unity Biotechnology continue to attract significant capital. Family office direct investment opportunities emerging in Series B/C rounds.
Multi-omics aging clock companies moving toward commercial launch. B2B2C model (insurance + wellness) gaining traction. Early-mover advantage in APAC market for longevity diagnostics.